The efficacy of immunotherapy in microsatellite stable colorectal cancer is limited. Here, the authors show that within the Phase II NIVACOR trial, genomic and transcriptomic profiling is associated with treatment activity.
- Angela Damato
- Riziero Esposito Abate
- Carmine Pinto
